# Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.

> **NCT04234594** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 94 (estimated)

## Conditions studied

- Healthy Males

## Interventions

- **DRUG:** QL1203
- **DRUG:** Vectibix®

## Key facts

- **NCT ID:** NCT04234594
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-28
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04234594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04234594, "Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04234594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*